SYDNEY, Jan. 30, 2026 /PRNewswire/ — SIA Booking Group Corporation (trading as EconomyBookings) acknowledges the Australian Competition and Consumer Commission’s (ACCC) infringement notices and allegations regarding aspects of how prices were displayed to consumers on our website in the Australian market. The company has paid penalties totalling A$39,600.

The pricing display practice in question is no longer used. “We have updated our booking experience to make the total price more prominent earlier in the process, including any pre-selected optional extras, and to clearly label what is optional,” said Alens Baibekovs, Chairman of the Board, SIA Booking Group Corporation.

“We apologise to customers who may have experienced confusion as a result of this issue. While the total price was displayed prior to payment, we recognise that clearer pricing information earlier in the booking journey is important for customers to make informed choices.”

“We take this matter seriously. Our priority is honest, clear, and transparent communication with our customers. We are strengthening internal quality controls around pricing displays and compliance to ensure our customer experience meets both legal requirements and the standard of clarity customers expect,” Mr Baibekovs said.

Customers with questions about their booking can contact our customer support team through the websites contact form.

Payment of a penalty specified in an infringement notice is not an admission of a contravention of the Australian Consumer Law.

GUANGZHOU, China, Jan. 30, 2026 /PRNewswire/ — Youxin Technology Ltd (Nasdaq: YAAS) (the “Company” or “Youxin Technology”), a software as a service (“SaaS”) and platform as a service (“PaaS”) provider committed to helping retail enterprises digitally transform their businesses, today announced its financial results for the fiscal year ended September 30, 2025.

Mr. Shaozhang Lin, Chief Executive Officer of Youxin Technology Ltd, commented, “In fiscal year 2025, we successfully completed our initial public offering and a follow-on offering, which substantially improved the Company’s liquidity and strengthened financial foundation. A key part of the R&D progress was the successful integration of AI models into our PaaS platform, enabling the generation of complex customized code through natural language and conversational interaction, which significantly enhanced development efficiency and user experience. With AI-enhanced solutions, we have already attracted clients from a broader range of industries, including cosmetics and cruise lines, and have reinforced the scalability of our platform. In parallel, by serving customers across multiple industries, we continued to expand the functionality of our PaaS platform and build multi-industry service capabilities, laying a solid foundation for a potential performance inflection in fiscal year 2026.”

Mr. Lin added, “Fiscal year 2025 marked a year of execution and capability building. Total revenues reached $0.54 million, representing a 3% increase from fiscal year 2024, primarily driven by the restart of our customized customer relationship management (CRM) system development services. Our net loss for the year was largely attributable to non-recurring items, including IPO- and follow-on-offering-related professional fees, warrant-related expenses, and investment losses, rather than any deterioration in our core operating performance.”

Mr. Lin continued, “The successful acquisition of Celnet Technology Co., Ltd. on October 29, 2025 advanced our internationalization strategy and enhanced our ability to serve multinational and large domestic enterprises through its extensive Salesforce implementation experience, further improving the practicality and enterprise readiness of our PaaS platform. Looking ahead, we plan to fully commercialize our R&D achievements and aim to achieve operating breakeven by fiscal year 2026. We will continue to promote our PaaS and SaaS solutions across various sectors and, together with our partners, pursue opportunities to expand into international markets, positioning the Company to support customers’ overseas expansion and sustainable growth in 2026 and beyond.”

Fiscal Year 2025 Financial Overview

• Revenue was $0.54 million in fiscal year 2025, an increase of 3% from $0.52 million in fiscal year 2024.
• Gross profit was $0.18 million in fiscal year 2025, compared to $0.34 million in fiscal year 2024.
• Gross margin was 33% in fiscal year 2025, compared to 66% in fiscal year 2024.
• Net loss was $9.65 million in fiscal year 2025, compared to $1.28 million in fiscal year 2024, mainly due to the professional fees incurred during the IPO and the follow-up offering, investment loss, and loss on issuance of warrant liabilities.
• Cash was $9.91 million as of September 30, 2025, compared to $0.02 million as of September 30, 2024, significantly increasing cash reserves and liquidity.

Fiscal Year 2025 Financial Results

Revenues

Total revenues were $0.54 million in fiscal year 2025, an increase of 3% from $0.52 million in fiscal year 2024. The increase was mainly because the Company restarted the customized CRM system development services.

Revenue from professional services was $0.52 million in fiscal year 2025, an increase of 87% from $0.28 million in fiscal year 2024.

• Revenue from customized CRM system development services was $0.29 million in fiscal year 2025. The Company did not generate revenue from customized CRM system development services in fiscal year 2024. The increase was mainly due to the Company restarting the customized CRM system development service.
• Revenue from the additional function development services was $38,808 in fiscal year 2025, a decrease of 9% from $42,758 in fiscal year 2024. The decrease was mainly due to the less new needs of the function development from the existing clients for fiscal year 2025.
• Revenue from subscription services was $0.19 million in fiscal year 2025, a decrease of 18% from $0.23 million in fiscal year 2024. The decrease was mainly due to the decreasing customized CRM system development services from 2023 to 2024, which led to the Company to provide less subscription service in the following periods.

Cost of Revenues

Cost of revenues was $0.36 million in fiscal year 2025, an increase of 100% from $0.18 million in fiscal year 2024.

Gross Profit

Gross profit was $0.18 million in fiscal year 2025, compared to $0.34 million in fiscal year 2024.

Gross margin was 33% in fiscal year 2025, compared to 66% in fiscal year 2024. 

Operating Expenses

Operating expenses were $3.04 million in fiscal year 2025, compared to $1.73 million in fiscal year 2024.

• Selling expenses were $0.13 million in fiscal year 2025, an increase of 38% from $0.09 million in fiscal year 2024. The increase was mainly due to the increase in advertising and promotion expenses. The increase of advertising and promotion expenses by $25,661 or 3,270% was primarily due to an increase in putting effort to the business promotion to expand customer base for fiscal year 2025, compared to fiscal year 2024.
• General and administrative expenses were $2.75 million in fiscal year 2025, an increase of 454% from $0.50 million in fiscal year 2024. The increase for fiscal year 2025 was primarily due to the professional fees incurred during the IPO and the follow-up offering that were not directly attributable of the offerings were expensed as incurred.
• Research and development expenses were $0.16 million in fiscal year 2025, a decrease of 86% from $1.14 million in fiscal year 2024. The decrease was primarily attributed to the decrease in labor related costs including salary and welfare by $0.90 million or 94% for fiscal year 2025 compared to fiscal year 2024.

Other Income (Expense), Net

Total net other expense was $6.79 million in fiscal year 2025, compared to total net other income of $0.11 million in fiscal year 2024, primarily due to loss from investments of $2.74 million, issuance costs allocated to warrant liabilities of $0.88 million, and loss on issuance of warrant liabilities of $5.80 million in fiscal year 2025, partly offset by gains from change in fair value of warrant liabilities of $2.65 million.

Net Loss

Net loss was $9.65 million in fiscal year 2025, compared to $1.28 million in fiscal year 2024.

Basic and Diluted Loss per Share

Basic and diluted loss per share was $1.04 in fiscal year 2025, compared to $0.14 in fiscal year 2024.

Financial Condition

As of September 30, 2025, the Company had cash of $9.91 million, compared to $0.02 million as of September 30, 2024.

Net cash used in operating activities was $3.91 million in fiscal year 2025, compared to $0.73 million in fiscal year 2024.

Net cash used in investing activities was $3.03 million in fiscal year 2025, compared to net cash provided by investing activities of $360 in fiscal year 2024.

Net cash provided by financing activities was $16.79 million in fiscal year 2025, compared to $0.43 million in fiscal year 2024.

About Youxin Technology Ltd

Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses using its cloud-based SaaS product and PaaS platform to develop, use and control business applications without the need to purchase complex IT infrastructure. Youxin Technology provides a customized, comprehensive, fast-deployment omnichannel digital solutions that unify all aspects of commerce with store innovations, distributed inventory management, cross-channel data integration, and a rich set of ecommerce capabilities that encompass mobile applications, social media, and web-based applications. The Company’s products allow mid-tier brand retailers to use offline direct distribution to connect the management team, distributors, salespersons, stores, and end customers across systems, apps, and devices. This provides retailers with a comprehensive suite of tools to instantly address issues using real-time sales data. For more information, please visit the Company’s website: https://ir.youxin.cloud.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

For more information, please contact:

Youxin Technology Ltd.
Investor Relations Department
Email: ir@youxin.cloud

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

Philips is recognized for its market-leading innovation and comprehensive digital pathology ecosystem, driving global transformation in diagnostics and healthcare informatics

SAN ANTONIO, Jan. 30, 2026 /PRNewswire/ — Frost & Sullivan is pleased to announce that Philips has been awarded the 2025 Global Enabling Technology Leadership Recognition in the Digital Pathology–Healthcare Informatics sector for its outstanding achievements in delivering next-generation digital pathology innovation, accelerated workflow modernization, and clinical informatics. This recognition highlights Philips Healthcare’s consistent leadership in driving measurable outcomes, strengthening its global market presence, and delivering customer-centric innovation in an increasingly complex healthcare environment.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Philips Healthcare excels in both, demonstrating an ability to align long-term innovation strategy with global market demand while executing at scale with consistency and precision. “Philips leads the global healthcare industry in patent applications. This propensity for innovation has positioned the company at the forefront of one of the sector’s fastest-growing fields: digital pathology. Building on this legacy, Philips Healthcare has emerged as a global leader in digital pathology,” said Melissa Kenig, Senior Consultant at Frost & Sullivan.

Guided by a long-term growth strategy centered on digital innovation, customer partnerships, and scalable enterprise informatics, Philips has demonstrated a strong ability to adapt and lead in a rapidly evolving diagnostic ecosystem. The company’s sustained investments in digital pathology and AI-enabled^1,2 informatics have enabled it to deliver value across diverse clinical environments, from large academic medical centers to multi-site laboratory networks.

Innovation remains foundational to Philips Healthcare’s approach. Its integrated digital pathology portfolio, including high-performance slide scanners, a robust image management system, advanced AI-powered² workflows, cloud archiving by Cloud Data Services³, and full-lab workflow support, addresses the end-to-end needs of modern pathology practices. These capabilities are strengthened by the Philips IntelliSite Pathology Solution, the first digital pathology platform to receive FDA 510(k) clearance for primary diagnosis.

“As diagnostic demand grows and resources tighten, digital pathology is becoming foundational to modern care. Frost & Sullivan’s recognition underscores our commitment to turning innovation into meaningful impact by streamlining workflows, enabling collaboration, and accelerating diagnosis, while responsibly advancing AI to support better patient care,” said Martijn Hartjes, Business Unit Leader Clinical Informatics at Philips.

Philips’ commitment to customer experience further amplifies its global leadership. With more than 3,500 pathologists across over 40 countries leveraging Philips’ digital pathology platform, and over 38 million slides scanned globally, the company has built one of the largest, most clinically validated installed bases in the industry. Its structured implementation services, extensive training programs, and globally unified support organization ensure strong customer engagement, high system uptime, and seamless scalability across enterprise networks.

Frost & Sullivan commends Philips for setting the industry benchmark in competitive strategy, technology innovation, and global execution. Philips’s vision for open, interoperable, and AI-powered² digital diagnostics is shaping the future of digital pathology and redefining what is possible for healthcare organizations seeking to improve diagnostic accuracy, speed, and collaboration at scale.

Each year, Frost & Sullivan presents the Enabling Technology Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition honors organizations that are transforming their industries through forward-thinking innovation and growth excellence.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact:
Ashley Shreve
E: ashley.weinkauf@frost.com

About Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.